Wedell A, Ritzén E M, Haglund-Stengler B, Luthman H
Department of Clinical Genetics, Rolf Luft Center for Diabetes Research, Stockholm, Sweden.
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7232-6. doi: 10.1073/pnas.89.15.7232.
Lesions in the gene encoding steroid 21-hydroxylase [steroid hydrogen-donor: oxygen oxidoreductase (21-hydroxylating), EC 1.14.99.10] result in defective adrenal steroid synthesis; the severe forms are known as congenital adrenal hyperplasia. To facilitate complete characterization of mutations in this region of tandemly repeated genes, we have developed selective PCR amplification and direct sequencing of full-length nonpseudogene steroid 21-hydroxylase genes. This technique identifies known mutations, characterizes or excludes unknown mutations, and determines the gene-copy number. Three additional defective alleles were found. A Gly-292----Ser mutation and a frameshift mutation at Arg-484 (GG----C) were identified in patients with severe steroid 21-hydroxylase deficiency. An allele with three additional sequence variations--C----T at 4 bases upstream of translation initiation, Pro-106----Leu, and Pro-454----Ser--were identified in two siblings with late-onset deficiency. Pro-454 is conserved in four species, indicating its importance for normal enzyme function. Functional consequences of individual alleles have been determined in vivo by studying individuals with only one steroid 21-hydroxylase gene. Detailed analyses of clinical data revealed that genotyping could predict the clinical course of the disease. The locations of disease-causing mutations on different haplotypes of the steroid 21-hydroxylase gene region are described.
编码类固醇21-羟化酶[类固醇氢供体:氧氧化还原酶(21-羟化),EC 1.14.99.10]的基因发生病变会导致肾上腺类固醇合成缺陷;严重形式称为先天性肾上腺增生。为了便于全面表征该串联重复基因区域中的突变,我们开发了全长非假基因类固醇21-羟化酶基因的选择性PCR扩增和直接测序技术。该技术可识别已知突变,表征或排除未知突变,并确定基因拷贝数。我们发现了另外三个缺陷等位基因。在严重类固醇21-羟化酶缺乏症患者中鉴定出一个Gly-292→Ser突变和一个位于Arg-484(GG→C)的移码突变。在两名迟发性缺乏症的兄弟姐妹中鉴定出一个具有三个额外序列变异的等位基因——翻译起始上游4个碱基处的C→T、Pro-106→Leu和Pro-454→Ser。Pro-454在四个物种中保守,表明其对正常酶功能的重要性。通过研究只有一个类固醇21-羟化酶基因的个体,已在体内确定了各个等位基因的功能后果。对临床数据的详细分析表明,基因分型可以预测疾病的临床进程。本文描述了类固醇21-羟化酶基因区域不同单倍型上致病突变的位置。